Skip to main content Skip to search Skip to main navigation

ICH: Assembly Meeting 2025

The ICH Assembly met on 18–19 November 2025 in Singapore and welcomed NAFDAC (Nigeria) and SAHPRA (South Africa) as new members, along with two new observers. Elections were held for leadership roles across the Assembly, Management Committee, and MedDRA Steering Committee.

Several major guidelines reached Step 4, including:

  • M11 CeSHarP (harmonized electronic clinical protocol)
  • E2D(R1) on post-approval safety data reporting
  • M14 on RWD-based pharmacoepidemiology studies

Three important draft guidelines entered Step 2b public consultation:

  • E22 (Patient Preference Studies)
  • Q3E (Extractables & Leachables)
  • E20 (Adaptive Clinical Trial Designs)

MedDRA is now available in 27 languages, and the new LMS shows strong uptake. ICH also introduced a new training strategy, including the use of AI tools.

Five experts received the ICH Award 2025 for outstanding contributions. To mark 35 years of ICH, a new communication campaign and an official LinkedIn account were launched. The next Assembly meeting will take place in June 2026 in Rio de Janeiro.


Source:

ICH: Press release, ICH Assembly Meeting, Singapore, November 2025

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

ICH: Updated Q9(R1) Briefing Pack

ICH: Updated Q9(R1) Briefing Pack

The ICH has fully revised the Q9(R1) Briefing Pack (March/April 2026) to align with the updated ICH Q9 guideline.
Read more
EMA: New Plans for the EU GMP Guide

EMA: New Plans for the EU GMP Guide

EMA published the GMDP Inspectors Working Group’s new 2026-2028 work plan and its 2025 annual report.
Read more
EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA launched a pilot under which EEA GMP inspectors will assess how sites demonstrate the effectiveness of their pharmaceutical quality system for risk-based change management, and whether the EEA GMP certificate could serve as the main evidence of this effectiveness.
Read more
EMA: Updated Guideline on Active Substance Chemistry

EMA: Updated Guideline on Active Substance Chemistry

The EMA has updated guidance on the information required for the manufacture and control of active substances used in medicinal products, with a 1 September 2026 date of application.
Read more
EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA added a new GMP/Q&A section on its website and published a dedicated Q&A document on 3D printing (3DP) for solid oral dosage forms.
Read more
Microbiological Monitoring – Sources of Contamination

Microbiological Monitoring – Sources of Contamination

All pharmaceutical dosage forms must be manufactured under controlled microbiological conditions. This requires microbial monitoring. This applies not only to sterile manufacturing, but also to facilities that manufacture non-sterile products.
Read more
Previous
Next